First-Line SGLT2 Inhibitor for Heart Failure with Reduced Ejection Fraction
Either dapagliflozin 10 mg daily or empagliflozin 10 mg daily should be used as first-line SGLT2 inhibitor therapy for patients with heart failure with reduced ejection fraction (HFrEF), as both agents have equivalent strong evidence for reducing cardiovascular death and heart failure hospitalization. 1
Evidence-Based Recommendation
The most recent 2025 Canadian Cardiovascular Society/Canadian Heart Failure Society guidelines explicitly recommend both dapagliflozin and empagliflozin as first-line SGLT2 inhibitors for HFrEF with equal standing 2. The 2021 CCS/CHFS guidelines provide a Strong Recommendation with High-Quality Evidence that "an SGLT2 inhibitor, such as dapagliflozin or empagliflozin, be used in patients with HFrEF, with or without concomitant type 2 diabetes, to improve symptoms and quality of life and to reduce the risk of HF hospitalization and/or CV mortality" 1.
Dosing Specifications
Dapagliflozin:
Empagliflozin:
Why Both Agents Are Equivalent
The landmark trials DAPA-HF (dapagliflozin) and EMPEROR-Reduced (empagliflozin) both demonstrated significant reductions in HF hospitalization and cardiovascular death in patients with HFrEF, regardless of diabetes status 1. A meta-analysis of these two trials showed consistent benefits: 13% reduction in all-cause death (HR 0.87,95% CI 0.77-0.98), 14% reduction in cardiovascular death (HR 0.86,95% CI 0.76-0.98), and 26% reduction in cardiovascular death or first HF hospitalization (HR 0.74,95% CI 0.68-0.82) 4. Importantly, tests for heterogeneity between the two trials were not significant, confirming equivalent efficacy 4.
Practical Selection Between the Two Agents
Since guidelines do not support a specific sequence or preference between dapagliflozin and empagliflozin 2, selection should be based on:
Choose Dapagliflozin if:
- Patient has concomitant chronic kidney disease with albuminuria (eGFR 25-75 mL/min/1.73 m² with proteinuria), as DAPA-CKD trial showed 44% reduction in renal outcomes and 31% reduction in cardiovascular death or HF hospitalization 1
- Simplicity is preferred (no titration required—start and stay at 10 mg daily)
- Patient has eGFR 25-30 mL/min/1.73 m² (DAPA-HF excluded patients with eGFR <30, but dapagliflozin has specific renal protection data down to eGFR 25) 1
Choose Empagliflozin if:
- Patient has type 2 diabetes with established atherosclerotic cardiovascular disease (broader diabetes indication) 1
- Patient has eGFR 20-30 mL/min/1.73 m² (EMPEROR-Reduced excluded patients with eGFR <20 vs. <30 for DAPA-HF) 1
- Dose flexibility is desired (can titrate from 10 to 25 mg if needed)
Either Agent Works Equally Well if:
- Patient has HFrEF without the specific considerations above
- Cost and formulary access are equivalent
- Patient preference exists for once-daily dosing (both are once daily)
Critical Implementation Points
Start SGLT2 inhibitors early in the disease course. While the landmark trials initiated therapy on top of maximally tolerated guideline-directed medical therapy (GDMT), recognizing the significant residual risk in HFrEF patients, it is reasonable to start SGLT2 inhibitors early rather than waiting for complete GDMT optimization 1. The 2025 guidelines explicitly state that "the literature currently does not support a specific sequence to initiating therapy" and that SGLT2 inhibitors can be initiated in any order alongside other GDMT components 2.
No titration is required for dapagliflozin (start and maintain at 10 mg daily), while empagliflozin may be titrated from 10 to 25 mg daily based on tolerability 2, 3.
Safety Considerations and Monitoring
Common Pitfalls to Avoid:
Genital mycotic infections (GMIs) are the most common adverse effect (10-15% risk in women, higher in uncircumcised men and those with previous GMIs). These typically can be managed with antifungal drugs without discontinuing therapy 1.
Temporary eGFR reduction up to 15% may occur, which generally resolves within 1-3 months. Do not discontinue therapy for this expected hemodynamic effect 1.
eGFR thresholds:
- EMPEROR-Reduced excluded eGFR <20 mL/min/1.73 m²
- DAPA-HF excluded eGFR <30 mL/min/1.73 m²
- Data supporting use with eGFR <30 mL/min/1.73 m² are very limited 1
Contraindications:
- Type 1 diabetes (absolute contraindication) 1
- End-stage renal disease requiring dialysis 5
- Pregnancy or lactation 5
Monitoring Requirements:
Monitor for volume depletion, particularly in patients on high-dose diuretics or with borderline blood pressure. However, SGLT2 inhibitors enhance diuretic efficiency without adverse renal impacts and actually reduce hypotension risk compared to concerns 6.
SGLT2 inhibitors reduce hyperkalemia risk, allowing better optimization of mineralocorticoid receptor antagonists and other GDMT 6.
Integration with Other GDMT
SGLT2 inhibitors are now one of the four foundational medication classes for HFrEF (alongside ARNI/ACEi/ARB, beta-blockers, and mineralocorticoid receptor antagonists) 7, 8. The 2022 AHA/ACC/HFSA guidelines elevated SGLT2 inhibitors to Class 1 recommendation status for HFrEF 7, 8.
In the landmark trials, approximately 11-19% of patients were on sacubitril-valsartan, 7.5-12% had cardiac resynchronization therapy, and 26-31% had implantable cardioverter-defibrillators, with no treatment interactions observed 1. This confirms SGLT2 inhibitors work synergistically with all other HF therapies.
Bottom Line Algorithm
- Diagnose HFrEF (LVEF ≤40%)
- Check eGFR and diabetes status
- If eGFR ≥30 mL/min/1.73 m²: Start either dapagliflozin 10 mg daily OR empagliflozin 10 mg daily
- If eGFR 25-30 mL/min/1.73 m² with albuminuria: Prefer dapagliflozin 10 mg daily
- If eGFR 20-30 mL/min/1.73 m²: Consider empagliflozin 10 mg daily
- If eGFR <20 mL/min/1.73 m²: Insufficient evidence; avoid use
- Initiate early—do not wait for complete GDMT optimization
- Educate about GMI risk and sick day management
- Monitor eGFR at 1-3 months (expect temporary decline up to 15%)
- Continue indefinitely unless contraindications develop